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a b s t r a c t 
This work addresses the multi-objective optimisation of manufacturing strategies of monoclonal antibod- 
ies under uncertainty. The chromatography sequencing and column sizing strategies, including resin at 
each chromatography step, number of columns, column diameters and bed heights, and number of cycles 
per batch, are optimised. The objective functions simultaneously minimise the cost of goods per gram 
and maximise the impurity reduction ability of the puriﬁcation process. Three parameters are treated as 
uncertainties, including bioreactor titre, and chromatography yield and capability to remove impurities. 
Using chance constraint programming techniques, a multi-objective mixed integer optimisation model 
is proposed. Adapting both ε-constraint method and Dinkelbach’s algorithm, an iterative solution ap- 
proach is developed for Pareto-optimal solutions. The proposed model and approach are applied to an 
industrially-relevant example, demonstrating the beneﬁts of the proposed model through Monte Carlo 
simulation. The sensitivity analysis of the conﬁdence levels used in the chance constraints of the pro- 
posed model is also conducted. 
© 2018 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
1. Introduction 
The market of biopharmaceutical products is currently in a fast- 
development stage, in which the sales of monoclonal antibodies 
(mAbs) products, important biopharmaceutical drugs for the treat- 
ment of cancer, autoimmune diseases, cardiovascular disease, etc., 
have grown rapidly. There were approximately $90 billion global 
sales in 2015, representing about 58% of the sales of all biophar- 
maceuticals. It is expected that the worldwide sales will increase 
to $110 billion by 2018 and $150 billion by 2021 ( Levine and 
Cooney, 2017 ). In the manufacturing processes of the mAb prod- 
ucts, chromatography operations in the downstream processing 
(DSP) are critical steps, which not only represent a large proportion 
of the total manufacturing cost, but also play an important role in 
the determination of the purity of ﬁnal products. Thus, it is critical 
to identify the chromatography puriﬁcation process in the biophar- 
maceutical manufacturing processes to produce cost-effective and 
reliable high-purity biopharmaceutical drugs. 
Optimisation-based approaches exist in the literature for the 
optimal decision-making on downstream puriﬁcation processes. 
The optimal synthesis of protein puriﬁcation processes was ad- 
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dressed by developing mixed integer programming models and 
solution approaches ( Vassquez-Alvarez et al., 2001; Simeonidis 
et al., 2005; Natali et al., 2009; Polykarpou et al., 2011 ). A meta- 
heuristic optimisation approach with genetic algorithms was pro- 
posed and applied to the production of mAbs to optimise pu- 
riﬁcation sequences and chromatography column sizing strategies 
( Simaria et al., 2012 ). Mixed integer optimisation models were also 
proposed to determine the optimal development of bioprocesses, 
using a hybrid simulation-optimisation decomposition algorithm 
for solution ( Brunet et al., 2012 ). Mixed integer programming tech- 
niques were applied for the optimal chromatography column siz- 
ing decisions in mAb manufacturing with different facility con- 
ﬁgurations, to minimise the cost of goods per gram (COG/g) ( Liu 
et al., 2013a,b ). The same authors further extended these mod- 
els to integrate both chromatography sequencing and column siz- 
ing decisions using mixed integer linear fractional programming 
(MILFP), where Dinkelbach’s algorithm was adapted for solution 
approach ( Liu et al., 2014, 2015 ). Integrated decision tools com- 
bining bioprocess economics and optimisation were developed for 
the most cost-effective process ﬂowsheets in allogeneic cell ther- 
apy manufacturing ( Simaria et al., 2014; Hassan et al., 2015 ). Re- 
cently, another approach for the optimisation of biopharmaceuti- 
cal downstream processes was developed by integrating detailed 
mechanistic models and artiﬁcial neural networks to maximise the 
https://doi.org/10.1016/j.compchemeng.2018.09.015 
0098-1354/© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
384 S. Liu, L.G. Papageorgiou / Computers and Chemical Engineering 119 (2018) 383–393 
Nomenclature 
Indices 
r resin 
s downstream step 
Sets 
CS set of chromatography steps including capture, inter- 
mediate puriﬁcation, polishing 
R s set of resins suitable to chromatography step s 
Parameters 
A l s conﬁdence level in chance constraint for LRV at chro- 
matography step s 
A t conﬁdence level in chance constraint for titre 
A 
y 
s conﬁdence level in chance constraint for yield at chro- 
matography step s 
brv bioreactor volume, L 
cy sr yield of resin r at chromatography step s 
cyd l s lower bound of triangular distribution of yield devia- 
tion at chromatography step s 
cyd 
p 
s peak of triangular distribution of yield deviation at 
chromatography step s 
cyd u s upper bound of triangular distribution of yield devia- 
tion at chromatography step s 
dem annual demand, g 
f parameter in Dinkelbach’s algorithm representing fac- 
tion from previous iteration 
lrv sr LRV of resin r at chromatography step s 
lrv d l s lower bound of triangular distribution of LRV deviation 
at chromatography step s 
lrv d p s peak of triangular distribution of LRV deviation at 
chromatography step s 
lrv d u s upper bound of triangular distribution of LRV devia- 
tion at chromatography step s 
maxbn maximum number of batches 
ncy s yield at non-chromatography step s 
titre upstream bioreactor titre, g/L 
titre l lower limit of triangular distribution of upstream 
bioreactor titre, g/L 
titre p peak of triangular distribution of upstream bioreactor 
titre, g/L 
titre u upper bound of triangular distribution of upstream 
bioreactor titre, g/L 
TLRV min minimum required total LRV of the process 
TLRV U upper bound of total LRV of the process 
α bioreactor working volume ratio 
δ parameter in Dinkelbach’s algorithm representing tol- 
erance of objective function 
TLRV incremental step of total LRV of the process 
σ batch success rate 
 triangular cumulative distribution function of uncer- 
tain titre 
¯s triangular cumulative distribution function of uncer- 
tain resin yield deviation 
˜ s triangular cumulative distribution function of uncer- 
tain resin LRV deviation 
Continuous Variables 
AP annual product output, g 
COG annual cost of goods, £
LRV s LRV at chromatography step s 
M 0 initial product mass entering downstream processes 
per batch, g 
M s product mass per batch after step s , g 
OBJ 1 objective 1: COG/g 
OBJ 2 objective 2: total LRV 
Binary Variables 
U sr 1 if resin r is selected at chromatography step s ; 0 oth- 
erwise 
Auxiliary Variables 
UM s −1 ,r ≡ U sr · M s −1 
yield of a process with three different chromatographic columns 
( Pirrung et al., 2017 ). 
In addition, dealing with uncertainty is also an important is- 
sue investigated in the literature on the optimisation of biophar- 
maceutical manufacturing process, which is sensitive to uncertain 
process parameters. The cost-effective equipment sizing strategies 
of a real puriﬁcation process were addressed and a combinatorial 
closed-loop optimisation problem was formulated and solved by 
evolutionary algorithm, considering uncertain titre ( Allmendinger 
et al., 2012, 2014a ). An optimisation framework was developed to 
address the integrated optimisation of both upstream processing 
(USP) and DSP of the mAb manufacturing, including bioreactor siz- 
ing and chromatography sequencing and column sizing strategies, 
under uncertainties in titre and chromatography yield. A chance 
constrained programming (CCP) based mixed integer linear pro- 
gramming (MILP) model was developed to tackle the uncertain- 
ties there ( Liu et al., 2016 ). A Markov decision model was devel- 
oped to identify the optimal condition-based bioreactor harvesting 
policies, and the IgG 1 antibody production was investigated as a 
case study ( Martagan et al., 2016 ). Ensemble modelling approach 
was used to account for uncertainties in bioprocess optimisation 
involving maximisation of the lower conﬁdence bound of the de- 
sired bioprocess objective, using a mean-standard deviation util- 
ity function, and was applied to a mAb batch production problem 
( Liu and Gunawan, 2017 ). An optimisation framework, including a 
Markov decision model and state space structural analysis, was de- 
veloped to deal with the trade-offs between yield and purity, start- 
ing material uncertainties, puriﬁcation capability limitations, and 
interlinked decisions involving multiple puriﬁcation steps for engi- 
neered proteins ( Martagan et al., 2018 ). 
All above works considered only single objective for optimisa- 
tion, while in the real practice, there is more than one criterion to 
measure the performance of manufacturing processes, which need 
to be taken into account simultaneously when optimising the rel- 
evant strategies, in order to achieve a balance among them. An 
optimisation framework with an evolutionary multi-objective op- 
timisation algorithm was developed to consider multiple objec- 
tives, including COG/g, robustness in COG/g, and impurity removal 
capabilities, in the optimisation of mAb manufacturing process 
( Allmendinger et al., 2014b ) Another decision-making framework 
on rapid resin selection in biopharmaceutical puriﬁcation process 
development considered both yield of puriﬁcation process and pu- 
rity of the target protein as objective functions, which were op- 
timised by a mathematical programming model ( Liu et al., 2017 ). 
Recently, a deterministic multi-objective optimisation model of a 
biopharmaceutical manufacturing process was developed to opti- 
mise both the cost and impurity removal capabilities of the puriﬁ- 
cation process ( Liu and Papageorgiou, 2018 ). 
In this work, the model in Liu et al. (2014) is ex- 
tended to address the multi-objective optimisation of bio- 
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Fig. 1. A typical mAb manufacturing process. 
pharmaceutical manufacturing processes under uncertainty. 
Both chromatography sequencing and column sizing strate- 
gies of a mAb puriﬁcation process are determined in or- 
der to achieve optimal COG/g and impurity removal ca- 
pability at the DSP. Uncertainties in titre, chromatography 
resin yield and impurity reduction ability are taken into 
account, which have a signiﬁcant impact on the economic 
and production eﬃciency of the process, respectively. A CCP-based 
multi-objective mixed integer optimisation model is proposed 
to handle the uncertainties, and eﬃcient solution approaches 
are developed for Pareto-optimal solutions. To the best of our 
knowledge, it is the ﬁrst attempt in the literature to develop 
mathematical programming-based models to solve multi-objective 
optimisation problems of biopharmaceutical manufacturing under 
uncertainty. 
The remaining of this paper is organised as follows: 
Section 2 describes the multi-objective optimisation problem. 
The mathematical formulation of the proposed optimisation model 
is given in Section 3 , followed by the proposed solution approach 
in Section 4 . Section 5 presents an industrially-relevant example, 
and the computational results of optimisation and simulation are 
shown and discussed in Section 6 . Finally, the concluding remarks 
are drawn in Section 7 . 
2. Problem statement 
In this work, a multi-objective optimisation problem of the mAb 
manufacturing strategies, including the chromatography sequenc- 
ing and column sizing strategies in the DSP, under uncertainty are 
addressed, to optimise both COG/g and impurity removal capability 
of a mAb puriﬁcation process illustrated in Fig. 1 . In this process, 
after mammalian cells cultured in bioreactors at the USP, the mAb 
is recovered, puriﬁed and cleared from potential viruses and impu- 
rities in the DSP with three packed-bed chromatography steps for 
capture, intermediate puriﬁcation and polishing, respectively. 
In each chromatography step, the resin is determined among 
a number of suitable candidates, which are categorised in to dif- 
ferent types. It is assumed that at most one resin is allowed to 
be selected from the candidates in each type into the sequence to 
utilities the orthogonal separation mechanisms. Besides the chro- 
matography sequencing decisions for resin selection, chromatogra- 
phy column sizing strategies are also to be determined, including 
the bed heights, diameters, number of chromatography columns, 
as well as the number of running cycles per batch. The optimal 
decisions are chosen from a set of given discrete candidate values. 
Similar to the previous work ( Liu et al., 2013a,b, 2014, 2015 ), the 
COG/g, which is equal to the annual total cost of goods (COG) di- 
vided by the annual total output, is aimed to be minimised in this 
work. In addition, the impurity removal capability of the puriﬁca- 
tion process is maximised as another objective function. Therefore, 
a bi-objective optimisation problem is considered in this work. 
To model the impurity removal capability, the host cell proteins 
(HCPs), produced or encoded by the organisms and unrelated to 
the intended mAb product, are investigated as the critical impu- 
rity in this work, and must be removed during DSP ( Levy et al., 
2014 ), due to their antigenic effects in patients. Each candidate 
resin’s logarithmic removal value (LRV) of HCPs is given, a measure 
of the resin’s HCPs removal capability deﬁned as the logarithm of 
the ratio of concentrations of HCPs in the outﬂow and inﬂow of 
the resin. The total LRV of the process is the summation of LRVs 
of all resins selected in the process, and therefore affected by the 
chromatography sequencing strategies. 
The key parameters in this problem, bioreactor titre and the 
chromatography yield and LRV of each resin, are associated with 
uncertainty, due to the ﬂuctuations in USP and sensitivity of op- 
erating conditions. In this work, the above mentioned three uncer- 
tain parameters are assumed to follow triangular probability distri- 
butions ( Stonier et al., 2013; Allmendinger et al., 2012, 2014a,b ). It 
is also assumed that the realised values of each uncertain parame- 
ter remain the same in different batches ( Liu et al., 2016 ). 
The multi-objective optimisation problem addressed in this 
work can be described as follows: 
Given are: 
• manufacturing process of a mAb product; 
• upstream bioreactor titre; 
• candidate chromatography resins at each step, and their key 
characteristics, e.g., yield, linear velocity, buffer usage, dynamic 
binding capacity, and LRV of HCPs; 
• key characteristics of non-chromatography steps, e.g., yield, 
time and buffer usage; 
• relevant cost data, e.g., reference equipment costs, labour wage, 
resin, buffer and media prices; 
• candidate column diameters and heights, numbers of columns 
and cycles; 
• probability distributions of titre, chromatography yields and 
LRVs of HCPs; 
To determine: 
• chromatography sequencing strategies, i.e., resin at each chro- 
matography step; 
• chromatography column sizing strategies, i.e., column diameter 
and bed height, number of columns, and number of cycles per 
batch at each chromatography step; 
• product mass and volume, and buffer usage volume; 
• number of total completed batches; 
• annual total processing time; 
So as to: 
minimise the COG/g and maximise the total LRV of the whole mAb 
puriﬁcation process. 
386 S. Liu, L.G. Papageorgiou / Computers and Chemical Engineering 119 (2018) 383–393 
3. Mathematical formulation 
In this section, a CCP-based multi-objective optimisation model 
for the optimal chromatography sequencing and sizing decisions is 
presented, to deal with uncertainties in titre and chromatography 
resin yields and LRVs of HCPs, based on the literature MILFP model 
for DSP puriﬁcation process optimisation ( Liu et al., 2014 ), which is 
given in the Supplementary Material. There are a large number of 
constraints and variables for the modelling of the highly complex 
process, including the product masses and volumes, buffer volumes 
and processing times in downstream operations, the calculation of 
relevant cost terms, and the linearisation the nonlinear constraints 
in the proposed optimisation model. Only the newly developed 
constraints in this work are presented in this section. 
The uncertain upstream titre, chromatography resin yields and 
LRVs of HCPs are tackled using the classic CCP approach, in which 
a risk tolerance is determined by the decision maker as a per- 
missible probability of violation in the constraints involving uncer- 
tain parameters ( Charnes and Cooper, 1959 ). The developed chance 
constraints are transformed into their deterministic equivalent for- 
mulations using the expression of the inverse cumulative distribu- 
tion function. The chance constraints for three parameter sets in 
the CCP approach are presented next in this section. 
3.1. Chance constraints for uncertain titre 
In the deterministic model, the initial protein mass from the 
upstream processes in each batch, M 0 , is determined by the biore- 
actor titre, titre , and the working volume of bioreactor: 
M 0 = t it re · α · brv (1) 
where α is the working volume ratio of the bioreactor, and brv 
is the volume of the single bioreactor, estimated by a rule-based 
method ( Simaria et al., 2012; Liu et al., 2013a,b, 2016 ), as follows: 
brv = dem 
α · titre · maxbn · σ ·∏ s ∈ CS min 
r∈ R s 
cy sr ·
∏ 
s / ∈CS nc y s 
(2) 
where dem is the target demand; maxbn is the maximum batches 
allowed, determined by the number of bioreactors utilised; σ is 
batch success rate; and cy sr and ncy s are the yields at chromatog- 
raphy and non-chromatography steps, respectively. 
When the parameter, titre , becomes uncertain, to develop a 
chance constraint to model uncertainty, Eq. (1) is ﬁrstly converted 
into an inequality, as shown in Eq. (3) in which M 0 is upper- 
bounded as it is maximised to achieve the minimum COG/g: 
M 0 ≤ t it re · α · brv (3) 
The corresponding chance constraint is formulated by enforcing 
the probability of the inequality above a certain limit, as follows: 
Pr ( M 0 ≤ t it re · α · brv ) ≥ A t (4) 
where A t is a minimum prespeciﬁed probability that Eq. (3) will 
hold true, as conﬁdence level taking a value between 50% and 
100%. 
The above Eq. (4) can be written using the probability of the 
uncertain titre: 
1 − Pr 
(
t it re ≤ M 0 
α · brv 
)
≥ A t (5) 
Here, the upstream titre is assumed to follow a triangular 
probability distribution, Tr( titre l , titre p , titre u ), where titre l , titre p 
and titre u are lower bound, peak and upper bound, respectively. 
Its cumulative distribution function is denoted as ( titre ). Thus, 
Eq. (5) can be rewritten as Eq. (6) : 

(
M 0 
α · brv 
)
≤ 1 − A t (6) 
Using the inverse cumulative distribution function expression, 
the deterministic equivalent formulation of Eq. (3) is as follows: 
M 0 ≤ −1 
(
1 − A t 
)
· α · brv (7) 
For an isosceles triangular distribution where t it r e u − t it r e p = 
t it r e p − t it r e l = t it re , −1 ( 1 − A t ) = t it r e l + 
√ 
2( 1 − A t ) · t it re , if 
A t > 50%. The peak can also be used to estimate the bioreactor vol- 
ume in Eq. (2) . 
3.2. Chance constraints for uncertain yields 
The yield at a chromatography step links the product mass 
amount in the inﬂow and outﬂow of the step, determined by the 
selected resin’s yield: 
M s = 
∑ 
r∈ R s 
c y sr ·UM s −1 ,r , ∀ s ∈ CS (8) 
where UM s −1 ,r is an auxiliary variable to represent U sr · M s −1 , in 
which U sr is a binary variable to indicate whether resin r is se- 
lected at chromatography step s , and M s is the mAb mass of each 
batch after step s . 
To model the uncertainty of resin yield, we introduce an uncer- 
tain parameter, cyd s , to denote the deviation of the selected resin’s 
yield from its standard value, cy sr , at chromatography step s . Thus, 
we can convert the constraint involving the uncertainty of resin 
yields into an inequality as follows: 
M s ≤
∑ 
r∈ R s 
c y sr ·UM s −1 ,r · cy d s , ∀ s ∈ CS (9) 
Similarly, given a conﬁdence level of Eq. (9) being true for each 
chromatography step s , A 
y 
s , its corresponding chance constraint can 
be formulated as: 
Pr 
( 
M s ≤
∑ 
r∈ R s 
c y sr ·UM s −1 ,r · cy d s 
) 
≥ A y s , ∀ s ∈ CS (10) 
Here, the yield deviation, cyd s , is an uncertain parameter fol- 
lowing a triangular distribution, Tr ( cyd l s , cyd 
p 
s , cyd 
u 
s ) . The peak cyd 
p 
s 
is 100%, while cyd l s and cyd 
u 
s are lower and upper bounds of the 
yield deviation at chromatography step s . The cumulative distribu- 
tion function is denoted as ¯s ( cy d s ) . Thus, similar to the discus- 
sion to titre in Section 3.1 , Eq. (10) can be reformulated as below: 
M s ≤ ¯−1 s 
(
1 − A y s 
)
·
∑ 
r∈ R s 
c y sr ·UM s −1 ,r , ∀ s ∈ CS (11) 
where ¯−1 s ( 1 − A y s ) = cyd l s + 
√ 
2( 1 − A t ) · c y d s , if c yd u s − c yd p s = 
cyd 
p 
s − cyd l s = cy d s and A y s > 50% . 
3.3. Chance constraints for uncertain LRVs 
To ensure the purity of the mAb product meets the target level 
after the puriﬁcation process, HCPs, one of the critical impurities, 
must be removed during the process. The capability to remove 
HCPs of each resin is measured in terms of LRV, lrv sr . Thus, the LRV 
at each chromatography step is determined by the selected resin: 
LR V s = 
∑ 
r∈ R s 
lr v sr ·U sr , ∀ s ∈ CS (12) 
To generate a chance constraint for uncertain LRV, Eq. (12) is 
converted into an inequality, with the introduction of an uncertain 
parameter, lrvd s , to represent the deviation of the selected resin’s 
LRV from its standard value at chromatography step s, lrv sr : 
LR V s ≤
∑ 
r∈ R s 
l r v sr ·U sr · l rv d s , ∀ s ∈ CS (13) 
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where LRV s is restricted by an upper bound as it is aimed to be 
maximised at each step. 
Similarly, the corresponding chance constraint of Eq. (13) with 
a given conﬁdence level of its being valid, A l s , is as follows: 
Pr 
( 
LR V s ≤
∑ 
r∈ R s 
l r v sr ·U sr · l rv d s 
) 
≥ A l s , ∀ s ∈ CS (14) 
The uncertain LRV deviation, lrvd s , also follows a triangular dis- 
tribution, Tr ( l rv d l s , l rv d 
p 
s , l rv d u s ) , in which the peak, lrv d 
p 
s , is also 
100%, and lrv d l s and lrv d u s are the corresponding lower and upper 
bounds. Given its cumulative distribution, ˜ s ( lrv d s ) , we have the 
following deterministic equivalent formulation of Eq. (13) : 
LR V s ≤ ˜ −1 s 
(
1 − A l s 
)
·
∑ 
r∈ R s 
lr v sr ·U sr , ∀ s ∈ CS (15) 
Here, under an isosceles triangular distribution where 
l rv d u s − l rv d p s = l rv d p s − l rv d l s = l rv d s , we have ˜ −1 s ( 1 − A l s ) = 
l rv d l s + 
√ 
2( 1 − A l s ) · l rv d s when A l s > 50% . 
3.4. Objective functions 
This problem includes two objective functions to simultane- 
ously consider both cost and impurity reduction ability of the pu- 
riﬁcation process. The ﬁrst objective, COG/g, i.e., the ratio of the 
total COG, COG , to the annual production, AP , is minimised: 
Min OB J 1 = COG 
AP 
(16) 
The second objective considers the maximisation of total impu- 
rity removal capability, which is represented by total LRV of the 
process, deﬁned as the summation of the LRVs at all three chro- 
matography steps: 
Max OB J 2 = 
∑ 
s ∈ CS 
LR V s (17) 
Overall, the optimisation problem under uncertainty is for- 
mulated as a CCP-based multi-objective optimisation model (de- 
noted as MO –CCP) with chance constraints, Eqs. (7) , (11) , (15) , as 
well as other constraints, Eqs. (S.1)-(S.7), (S.9), (S.11)-(S.84) pro- 
vided in the Supplementary Material, and Eqs. (16) and (17) as 
the objective functions. When no uncertainty is considered, the 
deterministic optimisation model (denoted as MO-DET) includes 
Eqs. (12) , (S.1)-(S.84) in the Supplementary Material as constraints, 
and Eqs. (16) and (17) as the objective functions, which will be 
compared to the proposed MO –CCP model later in this work. 
4. Solution approach 
To solve the proposed multi-objective optimisation model in 
the above section, we adapt the classic ɛ -constraint method 
( Haimes et al., 1971 ; Chankong and Haimes, 1983 ), where only one 
objective is optimised and all other objectives are converted into 
constraints by setting an upper or lower bound to each of them, to 
achieve the minimum-cost solution under total LRV requirement. 
The obtained solutions are proven to satisfy the Pareto optimality 
( Miettinen, 1999 ). 
In the proposed multi-objective optimisation problem, between 
the two objectives, the COG/g is kept as the objective function, 
while the total LRV of HCPs is transformed as a constraint lim- 
ited by a lower bound. Thus, the multi-objective model MO-CCP is 
reformulated as a single-objective optimisation model, SO –CCP, as 
follows: 
Min COG 
AP 
s . t . 
∑ 
s ∈ CS 
LR V s ≥ T LR V min 
Eqs . ( 7 ) , ( 11 ) , ( 15 ) , ( S . 1 ) −( S . 7 ) , ( S . 9 ) , ( S . 11 ) −( S . 84 ) 
where TLRV min refers to the minimum required total LRV to ensure 
that the purity of ﬁnal products is higher than the given target pu- 
rity level. By changing the value of TLRV min , a set of Pareto-optimal 
solutions can be achieved. The above SO –CCP model solved in each 
iteration of ɛ -constraint method is an MILFP model. Similar to the 
work of Liu et al. (2014, 2015, 2018 ), the Dinkelbach’s algorithm 
( Dinkelbach, 1967 ) is applied to the MILFP model by iteratively 
solving a number of MILP models, MILP-CCP, deﬁned as follows: 
Min COG − f · AP 
s . t . 
∑ 
s ∈ CS 
LR V s ≥ T LR V min 
Eqs . ( 7 ) , ( 11 ) , ( 15 ) , ( S . 1 ) −( S . 7 ) , ( S . 9 ) , ( S . 11 ) −( S . 84 ) 
where f is a parameter whose value is updated by iterations. 
Overall, the proposed iterative solution approach integrating 
both ɛ -constraint method and Dinkelbach’s algorithm is illustrated 
in Fig. 2 . The proposed iterative solution procedure consists of 
solving a number of CCP-based MILP models iteratively, result- 
ing in a set of Pareto-optimal solutions of the developed multi- 
objective optimisation model under uncertainty, MO –CCP. Note 
that the similar procedure is also applicable to the deterministic 
multi-objective optimisation problem, MO-DET, by solving a collec- 
tion of deterministic MILP models. 
5. Case study 
In this section, an industrially-relevant example, based on a 
mAb puriﬁcation process in a biopharmaceutical company, is intro- 
duced to examine the applicability of the proposed models and ap- 
proaches. There are 11 candidate commercial resins in two modes, 
binding-elution (BE) and ﬂow-through (FT) and the following ﬁve 
types: 
• aﬃnity chromatography (AFF); 
• cation-exchange chromatography (CEX 
• anion-exchange chromatography (AEX); 
• mixed-mode chromatography (MM); 
• hydrophobic interaction chromatography (HIC). 
The characteristics of these resin candidates are shown in 
Table 1 , where the standard values of yield and LRV of each resin 
are shown, and their actual values during production may vary 
from those. 
As to the chromatography column sizing decisions, 11 discrete 
potential bed heights and 10 discrete potential diameters are avail- 
able for selection, as shown in Table 2 . There also could be up to 
4 parallel columns utilised at each chromatography step and each 
batch could run in at most 10 cycles. 
Here, multiple USP trains could be used to feed one DSP train. 
According to the previous work ( Liu et al., 2013a,b, 2014, 2015, 
2016, 2017 ), single bioreactor has higher cost eﬃciency than other 
cases. Therefore, only one bioreactor is considered in this case 
study, while multiple bioreactors can be easily accommodated into 
the proposed models. Considering a target demand of 500 kg, the 
volume of the single bioreactor can be calculated using Eq. (2) , 
which is 25,017 L. More data in the case study are given in the 
Supplementary Material (Tables S1-S3). The three uncertain param- 
eters considered in this work all follow isosceles triangular prob- 
ability distributions, as described in Table 3 . It is assumed that 
different chromatography steps use the same distribution function 
considering uncertain yield and LRV deviation. 
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Fig. 2. The proposed iterative solution approach of the proposed MO –CCP model. 
Table 1 
Characteristics of resin candidates. 
Resin Type Mode Binding 
capacity 
(g/L) 
Eluate 
volume 
(CV) 
Buffer 
volume 
(CV) 
Linear 
velocity 
(cm/h) 
Matrix 
lifetime 
(cycle) 
Matrix 
price 
(£/L) 
Standard yield Standard LRV of HCPs 
Cap. Int. Pol. Cap. Int. Pol. 
R1 AFF BE 50 2.3 37 150 100 9200 91% 95% - 3 1.5 - 
R2 AFF BE 30 2.3 37 300 100 6400 91% 95% - 3 1.5 - 
R3 AFF BE 50 2.3 37 800 100 9900 91% 95% - 3 1.5 - 
R4 AFF BE 30 2.3 37 10 0 0 100 90 0 0 91% 95% - 3 1.5 - 
R5 CEX BE 120 1.4 26 500 100 2500 86% - - 2 - - 
R6 CEX BE 40 1.4 26 300 100 400 86% 92% 92% 2 1 0.5 
R7 AEX FT 100 0 10 300 100 700 - 95% 95% - 0.5 0.3 
R8 MM FT 150 0 10 375 100 3500 - 90% 90% - 1.2 0.6 
R9 MM BE 50 1.4 26 100 100 1900 - 90% 90% - 1.5 0.8 
R10 MM BE 35 1.4 26 250 12 2700 - 90% 90% - 2 1 
R11 HIC BE 27.5 1.4 26 175 100 2500 - 89% 89% - 2 0.5 
Table 2 
Chromatography column size candidates. 
Decision Candidate values 
Bed height (cm) 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 
Diameter (cm) 50, 60, 70, 80, 90, 100, 120, 160, 180, 200 
Number of cycles 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 
Number of columns 1, 2, 3, 4 
Table 3 
Triangular probability distributions of uncertainty parameters. 
Parameter Lower bound Peak Upper bound 
titre 2 (g/L) 3 (g/L) 4 (g/L) 
cyd s 95% 100% 105% 
lrvd s 80% 100% 120% 
6. Results and discussion 
In this section, the proposed optimisation model and solution 
approach are applied to the above case study. Then, the obtained 
optimal manufacturing strategies are examined through Monte 
Carlo (MC) simulation. At last, the sensitivity analysis of conﬁdence 
level is conducted. All computational runs were implemented in 
GAMS 24.7 ( GAMS Development Cooperation, 2016 ) on a 64-bit 
Windows 7 based machine with Intel Core i5-3330 3.00 GHz pro- 
cessor and 8.0 GB RAM, using CPLEX as MILP solver. 
6.1. Optimal results 
The proposed multi-objective optimisation model, MO –CCP, as 
well as the deterministic model, MO-DET, as the base case for com- 
parison, are solved. The conﬁdence level of chance constraint feasi- 
bility in the MO –CCP model is set to 95%, i.e., A t = A y s = A l s = 95% . 
With a 95% conﬁdence level, −1 ( 1 − A t ) in Eq. (7) , ¯−1 s ( 1 − A y s ) 
in Eq. (11) and ˜ −1 s ( 1 − A l s ) in Eq. (15) are approximately equal to 
2.32, 96.58%, and 86.32%, respectively. 
To implement the proposed solution approach, the minimum 
total LRV requirement of the puriﬁcation process is initially set 
to 3.4 g/L, and then is gradually increased to 5 g/L ( TLRV U ) with a 
step of 0.2 g/L ( TLRV ), and therefore a Pareto curve consisting of 
9 Pareto-optimal solutions is obtained. The Pareto frontier of the 
MO –CCP model is compared with that of the MO-DET model in 
Fig. 3 , where the optimal chromatography sequence of each Pareto- 
optimal solution is also presented. Table 4 shows the optimal chro- 
matography column sizing decisions under each minimum total 
LRV requirement. 
Firstly, the optimal chromatography decisions of the MO-DET 
problem are focused on. R5 (CEX) is selected at the capture step 
when the minimum required total LRV is low ( < 4), but R3 (AFF) 
with a higher standard LRV (3) is chosen when the minimum re- 
quired total LRV increases, even it is much more expensive than 
R5. Meanwhile, R7 (AEX) is used for polishing at all optimal solu- 
tions. The actual total standard LRV of the whole process increases 
from 3.5 to 5.3, to meet the impurity removal capability require- 
ment. As to the chromatography column sizing decisions, only one 
chromatography column is used at all steps in all solutions, while 
the other decisions vary, except that only the column with a diam- 
eter of 100 cm is always used at the capture step. With increas- 
ing minimum required total LRVs, COG/g increases by 10% from 
£68.4/g to £75.2/g. 
Next, by comparing the solutions of MO –CCP to those of MO- 
DET, it can be seen that, for each minimum required total LRV, 
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Fig. 3. The optimal COG/g and chromatography sequences of the MO –CCP and MO-DET models. 
Table 4 
Pareto-optimal solutions of the MO –CCP and MO-DET models. 
Minimum total LRV Total standard LRV COG/g (£/g) Column diameter ∗ (cm) Column bed height ∗ (cm) No. of columns ∗ No. of cycles per batch ∗
Model MO-DET 3.4 3.5 68.4 100/50/70 15/15/17 1/1/1 4/10/6 
3.6 3.8 69.6 100/90/70 20/23/18 1/1/1 3/6/6 
3.8 3.8 69.6 100/90/70 20/23/18 1/1/1 3/6/6 
4.0 4.3 70.3 100/120/70 18/17/16 1/1/1 8/6/7 
4.2 4.3 70.3 100/120/70 18/17/16 1/1/1 8/6/7 
4.4 4.5 70.7 100/70/80 24/20/21 1/1/1 6/4/4 
4.6 4.8 72.5 100/160/60 18/23/21 1/1/1 8/2/7 
4.8 4.8 72.5 100/160/60 18/23/21 1/1/1 8/2/7 
5.0 5.3 75.2 100/180/70 16/22/18 1/1/1 9/3/6 
Model MO –CCP 3.4 4.3 97.9 100/120/60 16/19/22 1/1/1 7/4/5 
3.6 4.3 97.9 100/120/60 16/19/22 1/1/1 7/4/5 
3.8 4.5 98.9 90/70/80 23/20/20 1/1/1 6/3/3 
4.0 4.8 100.9 10 0/20 0/60 16/22/18 1/1/1 7/1/6 
4.2 5.3 104.1 100/160/60 16/21/21 1/1/1 7/3/5 
4.4 5.3 104.1 100/160/60 16/21/21 1/1/1 7/3/5 
4.6 5.5 109.1 100/160/100 16/21/19 1/1/1 7/3/5 
4.8 5.6 110.1 100/160/50 16/21/17 1/1/1 7/3/6 
5.0 5.8 112.3 100/160/160 16/21/15 1/1/1 7/3/2 
∗ values at capture/intermediate puriﬁcation/polishing chromatography steps 
Fig. 4. Average COG/g in MC simulation on the solutions of the MO –CCP (95% conﬁdence level) and MO-DET models. 
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Fig. 5. Mean total LRVs and probabilities of failing to meet LRV requirement in MC simulation on the solutions of the MO –CCP (95% conﬁdence level) and MO-DET models. 
Fig. 6. Mean total LRVs and probabilities of failing to meet LRV requirement in MC simulation on the solutions of the MO –CCP model under conﬁdence levels of 90%, 95% 
and 98%. 
the MO –CCP model usually chooses a different chromatography se- 
quence with higher total standard LRV than that of MO-DET model. 
For example, when the minimum required total LRV is 3.8, the 
MO –CCP model chooses a sequence of R3-R8-R7, which has a total 
standard LRV of 4.5, in order to guarantee that the realised total 
LRV is no less than the required level at the given conﬁdence level 
(95%), while the optimal sequence of the MO-DET model, R5-R3- 
R7, has a total LRV of 3.8 only, which will fail to meet the require- 
ment if the realisation is below expectation. Comparing the total 
standard LRVs in the solutions of two models, the sequence of the 
MO –CCP model is averagely 0.7 higher than that of the MO-DET 
model, and 0.8 higher than the minimum required total LRV. More- 
over, the selected sequence of the MO –CCP model is also more ex- 
pensive. Different from the solutions of MO-DET model, R5 is no 
longer a choice at the capture step, while R3 is used no matter 
whether the total LRV requirement is low or high. However, at the 
polishing step, although R7 (AEX) with relatively lower price and 
LRV is chosen in most cases, resins having higher LRVs are used 
when the impurity removal capability requirement increases. Due 
to the chance constraints on titre and yields, the selected column 
sizes of the MO –CCP model is smaller than the MO-DET model, 
leading to lower production. Similar to the deterministic case, the 
COG/g increases with increasing minimum required total LRV. Due 
to the higher cost and lower production, the obtained COG/g by 
optimising the MO –CCP model is over 40% higher than the MO- 
DET model. In the next section, we will conduct an analysis of 
MC simulation to highlight the beneﬁts of the proposed CCP-based 
model. 
6.2. MC simulation 
Here, a stochastic analysis is conducted to examine the im- 
pact of variability on the solutions by implementing MC simulation 
( Kroese et al., 2011 ). MC simulation analysis was implemented on 
the solutions obtained by both MO –CCP and MO-DET models. After 
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Fig. 7. Mean COG/g in MC simulation on the solutions of the MO –CCP model under conﬁdence levels of 90%, 95% and 98%. 
obtaining the optimal solutions of optimisation models, MC simu- 
lation analysis was conducted by solving the deterministic optimi- 
sation model, SO-DET, with ﬁxed design variables, including vari- 
ables for chromatography sequence, column volume and number of 
columns, to re-optimise all other operational variables, dependent 
on different realisations of uncertain parameters, titre, cyd s and 
lrvd s . In the proposed MC simulation, a total of 10 0 0 simulation 
runs is implemented for each Pareto-optimal solution. Here, for 
the random realisation of each simulation run, it is ﬁrstly checked 
whether the realised total LRV meet the minimum required to- 
tal LRV. If the realised total LRV is less the minimum required 
total LRV, the single objective optimisation model subject to the 
minimum required total LRV constraint is infeasible, and the ﬁnal 
product of the generated puriﬁcation process cannot meet the tar- 
get purity level, which is treated as wastes. In this case, we take 
£10 0 0/g as COG/g of this simulation run ( Liu et al., 2016 ), which 
can be considered as the cost of outsourcing purchase. Otherwise, 
when the realised total LRV is no less than the minimum required 
total LRV, we run the deterministic model, SO-DET, to minimise 
the COG/g subject to the minimum total LRV and other constraints. 
The performance of the MC analysis is examined using the mean 
COG/g in all simulation runs, which mimics the expected value of 
COG/g. In addition, the probability of failing to meet the minimum 
LRV requirement is examined for the robustness of the selected 
chromatography strategies. The procedure of MC simulation is de- 
scribed as follows: 
STEP 1. Fix the optimal chromatography sequences, 
column volumes and the number of columns 
obtained from the optimisation models; 
STEP 2. Generate random titre, yield deviations 
and LRV deviations, all following 
triangular probability distributions as 
given in Table 4 ; 
STEP 3. If the total LRV is lower than the minimum 
required total LRV, COG/g is set to 1000; 
Otherwise, solve the model SO-DET with the 
random parameters by the proposed solution 
approach in Section 4 to obtain the optimal 
COG/g; 
STEP 4. Go to Steps 2 and 3 and repeat for 1000 
times. 
Fig. 4 shows the mean values of COG/g in the MC simulation. 
The mean values of COG/g in the MC simulation on the solutions 
of the MO –CCP model vary between £70/g and £90/g, which are 
lower than the optimal COG/g returned by the MO –CCP model, 
due to the underestimation of realisation of uncertain parame- 
ters in the chance constraints. Meanwhile, the mean values of 
COG/g in the MC simulation on the solutions of the MO-DET model 
are signiﬁcantly higher by one order of magnitude, up to £560/g. 
Fig. 5 shows another beneﬁt of the solutions MO –CCP model. The 
mean values of total LRV in the simulation on both MO –CCP and 
MO-DET models’ solutions are same as the total standard LRVs ob- 
tained by the optimisation models, as reported in Table 4 , which 
are all no less than the corresponding minimum required total 
LRVs. For the MO-DET model, the mean total LRV from the sim- 
ulation is not signiﬁcantly higher than the minimum required total 
LRV, with a difference of 0.3 at most and 0.1 on average. There- 
fore, the realised total LRV has a lower chance to meet the LRV re- 
quirement. For 9 Pareto-optimal solutions, the probabilities of total 
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LRV being lower than requirement are all greater than 10%, and the 
probabilities for two solutions are even more than 50% when the 
mean total LRV is the same as the minimum required value (3.8 
and 4.8). In the meantime, the solutions of MO –CCP model obtain 
chromatography sequences with much higher total LRVs, at least 
16% higher than the required values. Thus, there are just few sim- 
ulation runs whose realised total LRV is less than the minimum 
required total LRV, and the probability of failing to meet the re- 
quirement is 0% except for two solutions. When the minimum re- 
quired total LRV is high (4.8 and 5), only 1 or 2 simulation runs 
out of 10 0 0 cannot meet the requirement. The relatively higher to- 
tal LRV and lower probability of not meeting required purity level 
lead to the advantage of the solutions of the MO –CCP model. With 
smaller COG/g and lower failure rates, the MO –CCP model shows 
higher robustness, compared to the MO-DET model, to deal with 
the uncertainties in titre, resin yield and impurity removal capa- 
bility. 
Overall, the proposed MO –CCP model is able to cope with the 
uncertainties of the parameters, i.e., titre, resin yields and LRVs in 
this problem, to achieve signiﬁcant economic beneﬁts than the de- 
terministic counterpart. 
6.3. Sensitivity analysis of conﬁdence levels 
In the proposed CCP-based model, the conﬁdence levels in the 
chance constraints impact the probabilities of the solutions be- 
ing feasible. A risk-averse decision with a higher conﬁdence level 
makes the chance constraint to be held with higher probability. 
Here, it is assumed that the same conﬁdence level is implemented 
in all chance constraints. Three different conﬁdence levels, 90%, 
95% and 98%, are considered in this section. The optimal solutions 
obtained by the proposed MO –CCP model are examined using the 
MC simulation as described in the previous section. The details 
of the obtained optimal solutions with the 90% and 98% conﬁ- 
dence levels are provided in the Supplementary Material (Tables 
S4 and S5). In order to cope with low LRV realisation, the optimal 
solutions with higher conﬁdence levels select chromatography se- 
quences with higher total LRV, which are also more expensive, and 
incur lower probabilities of being lower than the requirement, as 
shown in Fig. 6 . When the conﬁdence level is 90%, the total LRVs of 
the chromatography sequence in the optimal solutions are smaller 
than the other two, and there are 6 solutions (out of 9) whose 
simulation runs cannot meet total LRV requirement, although the 
probability is quite low, only up to 2.5%. For the conﬁdence level 
of 98%, the selected sequences have the highest total LRVs, and the 
simulation runs of all solutions generate higher total LRVs than the 
minimum requirement. 
Consequently, as presented in Fig. 7 , a conﬁdence level of 90% 
achieves higher mean COG/g than the other two, except when the 
minimum required total LRV is 5, much more expensive resins 
are selected under the conference level of 98%, resulting in higher 
COG/g. The COG/g in the simulation under the conference levels 
of 95% and 98% are comparable to each other. It can be observed 
that the achieved mean values are quite similar. When the mini- 
mum required total LRVs are high (4.8 and 5), the conﬁdence level 
of 95% gets slightly smaller mean COG/g than the conference level 
of 98%, but has higher chance not to meet the minimum total LRV 
requirement. Especiﬁcally for this problem, conﬁdence levels rang- 
ing from 95% to 98% are applicable to chance constraints for high 
quality solutions. 
7. Concluding remarks 
This work addressed the multi-objective optimisation of down- 
stream processing of mAb products, to ﬁnd the optimal chromatog- 
raphy sequencing and column sizing strategies. Both cost and im- 
purity removal capability of the puriﬁcation process are considered 
as objectives. Considering uncertainties in bioreactor titre, chro- 
matography yield and LRV of HCPs, a stochastic CCP-based multi- 
objective optimisation model has been developed by extending 
previous work ( Liu et al., 2014 ). To solve the proposed model, ε- 
constraint method and Dinkelbach’s algorithm have been adapted 
to develop an iterative solution approach to generate a set of 
Pareto-optimal solutions with different minimum required total 
LRVs of the whole process. An industrially-relevant example has 
been investigated. The computational results of 9 Pareto-optimal 
solutions have shown that the CCP-based model deals with the 
variability of uncertain parameters in a better manner than the 
deterministic model, through the valuation of MC simulation, ob- 
taining much less mean COG/g. Also, a sensitivity analysis on the 
conﬁdence level shows the effects on the selected resin LRVs and 
COG/g in the MC simulation. 
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